exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274554 RNA Name: hsa-miR-155-5p RNA Type: miRNA Chromosome: chr21 Starnd: + Coordinate: Start Site(bp): 25573983 End Site(bp): 25574006 External Links: hsa-miR-155-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand TSC22D4 chr7 100463359 100479232 - ACOT7 chr1 6264269 6394391 - MRFAP1 chr4 6640091 6642745 + SH3KBP1 chrX 19533977 19887600 - NUFIP2 chr17 29255839 29294148 - CENPM chr22 41938737 41947152 - SP100 chr2 230415942 230545606 + ARL3 chr10 102673731 102714397 - JAK1 chr1 64833229 65067754 - LAPTM4A chr2 20032650 20051628 - SOD2 chr6 159669069 159745186 - HNRNPLL chr2 38561969 38603586 - LCP1 chr13 46125920 46211871 - AICDA chr12 8602170 8612867 - CD52 chr1 26317958 26320523 + MFSD9 chr2 102714630 102736888 - NDUFA4 chr7 10931943 10940153 - CHEK2 chr22 28687743 28742422 - ZMYM5 chr13 19823482 19863649 - PGLS chr19 17511636 17521288 + CCNB1 chr5 69167135 69178245 + IL2RG chrX 71107404 71112108 - CXXC1 chr18 50282343 50288304 - RBM38 chr20 57391396 57409333 + CFL1 chr11 65823022 65862026 - PPM1B chr2 44167969 44244384 + ZFP36 chr19 39406847 39409412 + FTL chr19 48965309 48966879 + ERH chr14 69380128 69398299 - VPS18 chr15 40894450 40903975 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000892 chr19 11941431 12014514 + hsa_circ_0001046 chr2 97024782 97033111 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000698 chr16 47531309 47549512 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC021078.1 chr5 149494314 149504670 - AC090198.1 chr8 124488510 124491643 + AC245033.4 chr15 82533175 82540008 - AL022311.1 chr22 37876148 37895563 + ELOA-AS1 chr1 23706901 23778296 - GABPB1-AS1 chr15 50354959 50372202 + LINC00240 chr6 26956932 27059749 + LINC01772 chr1 16460948 16468481 + MALAT1 chr11 65497688 65506516 + MIR155HG chr21 25561909 25575168 + MIR17HG chr13 91347820 91354579 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.